Related Experiment Videos
Misoprostol for cervical ripening and labor induction: a meta-analysis
L Sanchez-Ramos1, A M Kaunitz, R L Wears
1Department of Obstetrics and Gynecology, University of Florida Health Science Center, Jacksonville 32209, USA.
Obstetrics and Gynecology
|April 1, 1997
Summary
Misoprostol effectively ripens the cervix and induces labor, significantly reducing cesarean rates and shortening delivery times. While it increases tachysystole, it does not affect neonatal outcomes, confirming its safety and efficacy.
Area of Science:
- Obstetrics and Gynecology
- Reproductive Medicine
- Clinical Pharmacology
Background:
- Cervical ripening and labor induction are critical interventions in modern obstetrics.
- Misoprostol, a synthetic prostaglandin E1 analog, has been investigated for its role in these processes.
- Evaluating the existing evidence is crucial for informed clinical decision-making.
Purpose of the Study:
- To systematically analyze published randomized controlled trials (RCTs).
- To assess the safety and efficacy of misoprostol for cervical ripening and labor induction.
- To provide a meta-analysis of available data on misoprostol's obstetric outcomes.
Main Methods:
- Comprehensive literature search of electronic databases and reference lists.
- Inclusion of randomized trials evaluating misoprostol for cervical ripening and labor induction.
- Independent data abstraction and quality assessment by two blinded investigators; meta-analysis performed.
Main Results:
- Eight RCTs involving 966 patients were included in the meta-analysis.
- Misoprostol significantly reduced the cesarean delivery rate (OR 0.67) and increased vaginal delivery within 24 hours (OR 2.64).
- Associated with increased tachysystole (OR 2.70) but not hyperstimulation; similar neonatal outcomes and reduced induction-delivery interval (4.6 hours).
Conclusions:
- Published data strongly support the safety and efficacy of intravaginal misoprostol.
- Misoprostol is an effective agent for cervical ripening and labor induction.
- Clinical use is validated by evidence of improved delivery outcomes and comparable neonatal safety.